New ADHD Medication Centanafadine Receives FDA Approval

The Centanafadine FDA approval marks an important milestone in ADHD treatment, introducing a novel treatment approach for children, adolescents and adults living with this highly individualized disorder. Developed by Otsuka Pharmaceutical Development & Commercialization, Inc. and supported by clinical and preclinical data, the medication demonstrated statistically significant improvements in ADHD rating scale total scores compared with placebo across multiple age groups. This article explains how Centanafadine for the treatment of ADHD works, its novel mechanism as a serotonin reuptake inhibitor NDSRI, potential benefits and risks, and what healthcare professionals, patients, and families managing ADHD should know when making treatment decisions.

Centanafadine FDA Approval Marks a New ADHD Treatment Option

The FDA has approved Centanafadine, marketed as Simtriyo, as a new once-daily medication for the treatment of attention-deficit/hyperactivity disorder (ADHD). The Centanafadine FDA approval expands treatment options for adults and children age 6 and older who weigh at least 20 kilograms, offering a nonstimulant alternative for people who may not respond well to stimulant medications. Centanafadine works by affecting norepinephrine, dopamine, and serotonin activity in the brain. As ADHD affects millions of children and adults, this approval provides another evidence-based treatment option that may help improve symptom management as part of an individualized care plan.

What Is Centanafadine for Attention Deficit Hyperactivity Disorder?

Centanafadine is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat attention-deficit/hyperactivity disorder (ADHD). It is marketed under the brand name Simtriyo and is approved for adults and children age 6 and older who weigh at least 20 kilograms (44 pounds). Unlike traditional stimulant medications, Centanafadine is a nonstimulant that works by increasing the availability of norepinephrine, dopamine, and serotonin in the brain. By targeting multiple neurotransmitters involved in attention, impulse control, and executive functioning, it offers a new treatment approach for people living with ADHD.

What Is Centanafadine Used For?

Centanafadine is used to treat the core symptoms of ADHD, including inattention, hyperactivity, and impulsivity. It may help people improve concentration, complete tasks more consistently, stay organized, and better manage daily responsibilities at school, work, or home. Healthcare providers may recommend Centanafadine for patients who cannot tolerate stimulant medications, have certain medical considerations, or prefer a nonstimulant treatment option.

What the Centanafadine FDA Approval Means

The Centanafadine FDA approval gives patients and healthcare providers another evidence-based ADHD treatment option. The FDA accepted the New Drug Application in January 2026, expanding choices beyond stimulants and existing nonstimulants.

In an Otsuka Pharmaceutical press release, Chief Medical Officer John Kraus said ADHD in children, adolescents, and adults can significantly affect daily life. Today’s approval reflects the need for multiple therapeutic approaches supported by clinical teams, adolescent psychiatry, clinical psychopharmacology, NYU Langone Health, and Pediatrics Open Science.

Otsuka announced FDA Acceptance also noted that Centanafadine differs from a central nervous system stimulant regulated by the Drug Enforcement Administration. Executive Vice President statements ahead of an upcoming scientific meeting said patients continue to need more treatment options.

How Centanafadine Works for ADHD

Centanafadine affects neurotransmitter activity in the central nervous system by inhibiting the reuptake of norepinephrine, dopamine, and serotonin, allowing these neurotransmitters to remain active in the brain for a longer period. These chemical messengers play an important role in attention, motivation, impulse control, learning, and executive functioning. By improving communication between brain cells, Centanafadine may reduce ADHD symptoms without relying on the stimulant mechanisms used by medications such as methylphenidate or amphetamine.

Who May Be Eligible to Take Centanafadine, Including Pediatric Patients?

Centanafadine is FDA approved for adults and pediatric patients aged 6 and older who weigh at least 20 kilograms (44 pounds) and have a diagnosis of attention-deficit/hyperactivity disorder (ADHD). A healthcare provider will determine whether it is appropriate based on a person’s symptoms, medical history, current medications, cardiovascular health, treatment goals, and any co-occurring mental health or substance use disorders, and the label includes boxed warnings for abuse potential and monitoring for suicidal ideation in pediatric patients, especially children ages 6 to 12. Regular follow-up appointments help monitor symptom improvement, side effects, and the medication’s overall effectiveness.

Is Centanafadine a Stimulant or Nonstimulant?

Centanafadine is a nonstimulant ADHD medication and is not classified as a controlled substance. Unlike stimulant medications that primarily increase dopamine and norepinephrine through different mechanisms, Centanafadine acts as a norepinephrine, dopamine, and serotonin reuptake inhibitor. This difference may make it an appropriate option for some patients who cannot tolerate stimulant medications or have concerns about stimulant misuse.

Centanafadine Dosage and Treatment Use

Centanafadine is available as an extended-release capsule taken once daily. Recommended dosing depends on the patient’s age, weight, and prescribing guidelines, which may differ across Centanafadine dose groups, while healthcare providers may adjust treatment based on symptom improvement and side effects. Patients should take the medication exactly as prescribed and attend regular follow-up appointments so providers can monitor effectiveness, blood pressure, heart rate, and overall response to treatment.

Benefits of Centanafadine for ADHD Symptoms

• May improve attention and concentration
• May reduce hyperactivity and impulsivity
• Once-daily extended-release dosing
• Nonstimulant treatment option
• Not classified as a controlled substance
• May improve executive functioning
• May support school, work, and daily performance
• Expands treatment options for patients who cannot tolerate stimulants

Centanafadine Clinical Trial Results

Clinical trials found that Centanafadine significantly reduced ADHD symptoms compared with placebo in both adults and children. Studies also demonstrated improvements in attention, hyperactivity, and impulsivity while supporting an acceptable safety profile. The FDA approval was based on evidence showing that the medication was effective and generally well tolerated when used as directed. Otsuka Pharmaceutical Co. reported that its Adult ADHD Program and adolescent studies used randomized clinical trial data to evaluate high-dose Centanafadine across adult populations and ADHD in children and adolescents, supporting FDA acceptance, a priority review designation, and the July 24, 2026 target action date.

ADHD Prevalence in Children and Adults

ADHD is one of the most common neurodevelopmental disorders. Millions of children and adults in the United States, including those affected by adhd in children and adulthood, live with ADHD, and symptoms often continue into adulthood if left untreated. Early diagnosis and evidence-based treatment can improve academic performance, employment, relationships, and overall quality of life.

Effects and Risks of Centanafadine Treatment

Short-Term: common adverse events may include:

• Improved attention and focus
• Reduced hyperactivity and impulsivity
• Better task completion and organization
• Decreased appetite
• Difficulty sleeping
• Dry mouth
• Nausea
• abdominal pain
• Increased heart rate or blood pressure
• Headache
• Fatigue or dizziness

Long-Term:

• Continued improvement in ADHD symptom control
• Better school, work, and social functioning
• Ongoing monitoring of blood pressure and heart rate
• Possible changes in weight or appetite
• Need for regular follow-up to evaluate effectiveness
• Potential medication adjustments over time
• Unknown long-term safety beyond available clinical data as additional research continues

How ADHD Affects Mental Health and Daily Life

ADHD affects much more than attention. Many people experience anxiety disorders, major depressive disorder, bipolar disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), emotional dysregulation, chronic stress, low self-esteem, and sleep disorders alongside ADHD. Untreated symptoms can also contribute to frustration, irritability, social isolation, relationship conflict, poor academic or work performance, financial problems, and a higher risk of self-harm or suicidal thoughts in some individuals.

Executive functioning challenges often make it difficult to manage time, stay organized, complete tasks, regulate emotions, and maintain routines. Over time, these difficulties can increase stress, reduce quality of life, and worsen existing mental health conditions if left untreated.

ADHD and Co-Occurring Substance Use Disorders

People with ADHD have a higher risk of developing substance use disorders than the general population, especially when symptoms remain untreated. Research has linked ADHD with alcohol use disorder, cannabis use disorder, nicotine dependence, opioid use disorder, cocaine addiction, methamphetamine addiction, prescription stimulant misuse, benzodiazepine misuse, and polysubstance use.

Some individuals use alcohol, marijuana, nicotine, or stimulants to temporarily improve focus or reduce emotional distress, but repeated substance use often worsens ADHD symptoms, increases impulsivity, and raises the risk of dependence, overdose, and co-occurring mental health disorders. Early diagnosis and integrated treatment can reduce these risks and improve long-term outcomes.

Centanafadine Drug and Alcohol Interactions

Patients should tell their healthcare provider about all prescription medications, over-the-counter drugs, supplements, and herbal products before taking Centanafadine. Alcohol and recreational drugs, including cocaine, methamphetamine, cannabis, opioids, MDMA, and benzodiazepines, may increase side effects, worsen mental health symptoms, raise cardiovascular risks, or interfere with ADHD treatment. Healthcare providers can help identify potential drug interactions and determine whether Centanafadine is appropriate.

Misuse, Dependence, and Addiction Risks

Centanafadine is a nonstimulant medication and is not classified as a Schedule II controlled substance like many stimulant ADHD medications. Current evidence suggests it has a lower risk of misuse, physical dependence, and addiction than stimulant treatments such as amphetamine and methylphenidate. Even so, patients should take Centanafadine only as prescribed and discuss any history of substance use disorders with their healthcare provider.

How Centanafadine Compares With Other ADHD Medications

Unlike stimulant medications such as Adderall, Vyvanse, and Ritalin, Centanafadine is a nonstimulant that affects norepinephrine, dopamine, and serotonin through reuptake inhibition. Other nonstimulants, including atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay), work differently. Centanafadine expands treatment options for patients who cannot tolerate stimulants, have concerns about misuse, or need an alternative evidence-based ADHD medication.

Benefits of Treating ADHD and Addiction Together

• Treats ADHD and substance use disorders at the same time
• Reduces relapse risk by addressing underlying ADHD symptoms
• Improves focus, impulse control, and emotional regulation
• Supports recovery without relying on substances
• Treats co-occurring anxiety, depression, or PTSD
• Improves daily functioning and long-term outcomes

When to Seek Help

Seek professional help if ADHD symptoms interfere with school, work, relationships, or daily life, or if substance use or mental health symptoms develop. Early treatment can improve functioning and reduce the risk of addiction and worsening mental health conditions.

Treatment Options for ADHD and Co-Occurring Mental Health Conditions

• Medication Management – Prescription stimulant or nonstimulant medications monitored by a healthcare provider.
• Cognitive Behavioral Therapy (CBT) – Improves coping skills, organization, and emotional regulation.
• Individual and Family Therapy – Treats ADHD alongside anxiety, depression, PTSD, or other mental health conditions.
• Intensive Outpatient Programs (IOP) – Structured therapy for co-occurring ADHD and substance use disorders.
• Residential Treatment – Twenty-four-hour care for severe addiction or complex mental health needs.
• Peer Support Groups – Provide education, accountability, and ongoing recovery support.

Does Insurance Cover Treatment?

Many private insurance plans, Medicaid, and Medicare cover ADHD evaluations, therapy, psychiatric care, medications, and treatment for co-occurring mental health or substance use disorders. Coverage varies by plan, so patients should verify their benefits before starting treatment.

Conclusion

The Centanafadine FDA approval expands therapeutic choices for ADHD and reflects continued progress in advancing innovative treatment options for adult and pediatric populations. While clinical trials found statistically significant improvements, treatment decisions should remain individualized because ADHD manifests differently and many patients experience symptoms alongside other mental health or substance use disorders. Healthcare professionals can help determine whether Centanafadine is an appropriate option by considering medical history, potential side effects, and each person’s treatment goals.